In Vivo and in Vitro Suppression of T-Cell Receptor α/β CD4-CD8- T Lymphocytes by Cyclosporine A

Edward G. Brooks, Daniel P. Wirt, Gary R. Klimpel, Smita Vaidya, Randall M. Goldblum

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

We treated a patient with a combined immunodeficiency and disease pathology resembling GvHD with cyclosporine. This disorder was characterized by exfoliative dermatitis, lymphadenopathy, and lymphocytosis of a novel T-cell phenotype (CD3+ TCR α/β+ CD4- CD8-). The patient's peripheral blood T cells had elevated cytolytic activity and expressed increased levels of IL2R, HLA-DR, and CD45RO. Treatment with CsA resulted in marked clinical improvement, resolution of the lymphocytosis, and reduced cytolytic activity of peripheral blood T cells. T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells. CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR α/β+ CD4- CD8- cell lines. Our data suggest that alleviation of the patient's clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR α/β+ CD4- CD8- T lymphocytes in vivo. The response of this patient to cyclosporine, which was similar to that seen in true GvHD, provides further evidence that these conditions share common pathogenetic pathways.

Original languageEnglish (US)
Pages (from-to)224-231
Number of pages8
JournalClinical Immunology and Immunopathology
Volume67
Issue number3
DOIs
StatePublished - Jun 1993

Fingerprint

T-Cell Antigen Receptor
Cyclosporine
T-Lymphocytes
Lymphocytosis
HLA-DR Antigens
Blood Cells
Cytokines
Exfoliative Dermatitis
In Vitro Techniques
Pathology
Phenotype
Cell Line

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Immunology and Allergy
  • Immunology

Cite this

In Vivo and in Vitro Suppression of T-Cell Receptor α/β CD4-CD8- T Lymphocytes by Cyclosporine A. / Brooks, Edward G.; Wirt, Daniel P.; Klimpel, Gary R.; Vaidya, Smita; Goldblum, Randall M.

In: Clinical Immunology and Immunopathology, Vol. 67, No. 3, 06.1993, p. 224-231.

Research output: Contribution to journalArticle

Brooks, Edward G. ; Wirt, Daniel P. ; Klimpel, Gary R. ; Vaidya, Smita ; Goldblum, Randall M. / In Vivo and in Vitro Suppression of T-Cell Receptor α/β CD4-CD8- T Lymphocytes by Cyclosporine A. In: Clinical Immunology and Immunopathology. 1993 ; Vol. 67, No. 3. pp. 224-231.
@article{8d9a552ae5da41348b6b5698702368a2,
title = "In Vivo and in Vitro Suppression of T-Cell Receptor α/β CD4-CD8- T Lymphocytes by Cyclosporine A",
abstract = "We treated a patient with a combined immunodeficiency and disease pathology resembling GvHD with cyclosporine. This disorder was characterized by exfoliative dermatitis, lymphadenopathy, and lymphocytosis of a novel T-cell phenotype (CD3+ TCR α/β+ CD4- CD8-). The patient's peripheral blood T cells had elevated cytolytic activity and expressed increased levels of IL2R, HLA-DR, and CD45RO. Treatment with CsA resulted in marked clinical improvement, resolution of the lymphocytosis, and reduced cytolytic activity of peripheral blood T cells. T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells. CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR α/β+ CD4- CD8- cell lines. Our data suggest that alleviation of the patient's clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR α/β+ CD4- CD8- T lymphocytes in vivo. The response of this patient to cyclosporine, which was similar to that seen in true GvHD, provides further evidence that these conditions share common pathogenetic pathways.",
author = "Brooks, {Edward G.} and Wirt, {Daniel P.} and Klimpel, {Gary R.} and Smita Vaidya and Goldblum, {Randall M.}",
year = "1993",
month = "6",
doi = "10.1006/clin.1993.1069",
language = "English (US)",
volume = "67",
pages = "224--231",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - In Vivo and in Vitro Suppression of T-Cell Receptor α/β CD4-CD8- T Lymphocytes by Cyclosporine A

AU - Brooks, Edward G.

AU - Wirt, Daniel P.

AU - Klimpel, Gary R.

AU - Vaidya, Smita

AU - Goldblum, Randall M.

PY - 1993/6

Y1 - 1993/6

N2 - We treated a patient with a combined immunodeficiency and disease pathology resembling GvHD with cyclosporine. This disorder was characterized by exfoliative dermatitis, lymphadenopathy, and lymphocytosis of a novel T-cell phenotype (CD3+ TCR α/β+ CD4- CD8-). The patient's peripheral blood T cells had elevated cytolytic activity and expressed increased levels of IL2R, HLA-DR, and CD45RO. Treatment with CsA resulted in marked clinical improvement, resolution of the lymphocytosis, and reduced cytolytic activity of peripheral blood T cells. T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells. CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR α/β+ CD4- CD8- cell lines. Our data suggest that alleviation of the patient's clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR α/β+ CD4- CD8- T lymphocytes in vivo. The response of this patient to cyclosporine, which was similar to that seen in true GvHD, provides further evidence that these conditions share common pathogenetic pathways.

AB - We treated a patient with a combined immunodeficiency and disease pathology resembling GvHD with cyclosporine. This disorder was characterized by exfoliative dermatitis, lymphadenopathy, and lymphocytosis of a novel T-cell phenotype (CD3+ TCR α/β+ CD4- CD8-). The patient's peripheral blood T cells had elevated cytolytic activity and expressed increased levels of IL2R, HLA-DR, and CD45RO. Treatment with CsA resulted in marked clinical improvement, resolution of the lymphocytosis, and reduced cytolytic activity of peripheral blood T cells. T-cell HLA-DR and IL2R expression was reduced by cyclosporine, but CD45RO remained intact on virtually all circulating T cells. CsA also inhibited the cytolytic activity and cytokine production of in vitro cultured TCR α/β+ CD4- CD8- cell lines. Our data suggest that alleviation of the patient's clinical symptoms resulted from cyclosporine-mediated suppression of proliferation, cytotoxicity, and inflammatory cytokine production of TCR α/β+ CD4- CD8- T lymphocytes in vivo. The response of this patient to cyclosporine, which was similar to that seen in true GvHD, provides further evidence that these conditions share common pathogenetic pathways.

UR - http://www.scopus.com/inward/record.url?scp=0027155299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027155299&partnerID=8YFLogxK

U2 - 10.1006/clin.1993.1069

DO - 10.1006/clin.1993.1069

M3 - Article

VL - 67

SP - 224

EP - 231

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 3

ER -